These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 23337170)
1. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease? Bhalme M; Sharma A; Keld R; Willert R; Campbell S Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170 [TBL] [Abstract][Full Text] [Related]
2. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B; Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000 [TBL] [Abstract][Full Text] [Related]
3. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies. Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953 [TBL] [Abstract][Full Text] [Related]
4. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center. Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466 [TBL] [Abstract][Full Text] [Related]
6. Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Gremese E; Bernardi S; Bonazza S; Nowik M; Peluso G; Massara A; Tolusso B; Messuti L; Miceli MC; Zoli A; Trotta F; Govoni M; Ferraccioli G Rheumatology (Oxford); 2014 May; 53(5):875-81. PubMed ID: 24407233 [TBL] [Abstract][Full Text] [Related]
7. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period]. Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. Trinder MW; Lawrance IC J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669 [TBL] [Abstract][Full Text] [Related]
9. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease. Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255 [TBL] [Abstract][Full Text] [Related]
11. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942 [TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Allez M; Vermeire S; Mozziconacci N; Michetti P; Laharie D; Louis E; Bigard MA; Hébuterne X; Treton X; Kohn A; Marteau P; Cortot A; Nichita C; van Assche G; Rutgeerts P; Lémann M; Colombel JF Aliment Pharmacol Ther; 2010 Jan; 31(1):92-101. PubMed ID: 19709098 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Viola F; Civitelli F; Di Nardo G; Barbato MB; Borrelli O; Oliva S; Conte F; Cucchiara S Am J Gastroenterol; 2009 Oct; 104(10):2566-71. PubMed ID: 19550415 [TBL] [Abstract][Full Text] [Related]
14. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339 [TBL] [Abstract][Full Text] [Related]
15. Elective switching from infliximab to adalimumab in stable Crohn's disease. Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337 [TBL] [Abstract][Full Text] [Related]
17. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Feagan BG; Panaccione R; Sandborn WJ; D'Haens GR; Schreiber S; Rutgeerts PJ; Loftus EV; Lomax KG; Yu AP; Wu EQ; Chao J; Mulani P Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553 [TBL] [Abstract][Full Text] [Related]
18. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Ng SC; Plamondon S; Gupta A; Burling D; Kamm MA Aliment Pharmacol Ther; 2009 Oct; 30(7):757-66. PubMed ID: 19575762 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres. Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020 [TBL] [Abstract][Full Text] [Related]